Programme 2020
Nordic Precision Medicine Forum
3-4 November 2020, Stockholm
Scroll down for the full updated agenda.
For any enquiries about speaking opportunities or if you have an interest in hosting one of our workshops please email Amanda Rafferty
Image
Agenda HERE
DAY 1 - Tuesday November 3, 2020
#nordicpmf
11:00
Registration and Refreshments
11:30
Opening Remarks and an Update on Genomic Medicine Sweden from the Chair:
Prof Richard Rosenquist Brandell, Professor of Clinical Genetics, Department of Molecular Medicine and Surgery, Karolinska Institutet, Senior Physician, Clinical Genetics, Karolinska University Hospital, & Director, Genomic Medicine Sweden
Image
Image
11:45
Precision Medicine: National Initiatives and Regulation: Where We Are and Next Steps

A panel of expert speakers from across the Nordic region will outline current policy and regulations governing precision medicine, and the initiatives being implemented to further advance its implementation, in their specific countries. A panel discussion will then explore some of the following issues:

  • How can flexibility be built into policy development to enable regulatory frameworks to adapt and innovate as research and technology progresses?
  • To what extent can, or should, national regulations be harmonised, or common European policies adopted to facilitate and advance precision medicine?
  • Assessing where time, energy and investment should be best focused in order to implement precision medicine into the clinical setting
Dr Päivi Sillanaukee, Director General, Ministry of Social Affairs and Health, Finland
Image
Image
Dr Grethe S. FossProject Leader Personalised Medicine & Senior Adviser, The Norwegian Directorate of Health
Image
Image
Dr Kári StefánssonPresident, Chairman, CEO and Co-Founder, deCODE Genetics
Image
Image
Peter Johansen, Advisor, Healthcare Team, Danish National Genome Center
Image
Image
13:15
Networking Lunch
14:15
Determining Appropriate Governance to Manage the Legal & Ethical Considerations of Sharing and Using Biological & Healthcare Data
  • Determining the extent to which specific provision for scientific research within General Data Protection Regulation (GDPR) differs across European countries:
    • what frameworks, principles and norms have so far been developed to ensure an ethical approach to data sharing in health research?
  • Managing the balance between patient privacy rights and the benefits of data-sharing
    • understanding patients’ expectations of research and the societal benefits and value from it 
    • how do we generate and maintain patient trust with regards to their personal information?
  • Assessing the impact of AI and digital healthcare on data governance requirements
Heidi Beate Bentzen, Doctoral Research Fellow, The Centre for Medical Ethics, Faculty of Medicine and The Norwegian Research Center for Computers and Law, Faculty of Law, University of Oslo
Image
Image
   Dr Marjut Salokannel docent, Founding Partner, Salokannel Research & Consulting SaReCo Oy
Image
Image
15:15
Refreshments and Networking
15:40
Delegates move to their chosen break-out session
15:45
Interactive Break-Out Sessions

These focused, interactive sessions give you the opportunity to discuss a key topic of interest to you in a more participative format. Each session will be led by a facilitator who will lead the discussion and encourage maximum debate and sharing of ideas.

A. Intelligent Health: Unlocking the Potential in Life Course Digital Health Data
Prof Carsten Obel, Professor in General Medicine, Data, Innovation & Technology Public Health Lab, Department of Public Health, Aarhus University
Image
Image
B. Successfully Implementing Precision Medicine Research into Clinical Practice
Bogi Eliasen, Associated Partner, Health & Medicine, Genetics & Genomics, Public Policy, Copenhagen Institute for Future Studies
Image
Image
C. Getting Meaningful Outcomes from “Big Data”
D. NGS-Informed Prescribing - Predicting Drug Response and Adverse Drug Reactions to Advance Precision Medicine
Prof Dr Volker M Lauschke, Associate Professor in Personalized Medicine and Drug Development, & Director of Micro- and Nanofabrications Facility, Karolinska Institutet
Image
Image
E. Accessing Funding Mechanisms to Advance Health Innovation

This workshop will explore how we can take advantage of national and international funding schemes as well as Public-Private Partnerships & collaborations. What are the challenges and how can they be overcome?

Merike Leego, Innovation Manager, EIT Health Scandinavia
Image
Image
Dr Åsa Wallin, Portfolio Manager, Swelife
Image
Image
F. Advances in Biomarker Development & Validation for Enhanced Clinical Insights
G. Effectively Using Digital Biomarkers for Advanced Diagnostics and Personalised Healthcare
H. Panel Session Led by Apotekarsocieteten: The Development and Manufacture of More Precise Drug Delivery Systems, Drug Products & Drug Formulations

This session, led by Apotekarsocieteten, the Swedish Pharmaceutical Society, will comprise a series of short presentations on drug development for precision medicine, followed by a panel debate.

Chair: Dr Agneta Larhed, Senior Consultant, RegSmart Life Science & Drug Formulation Section, Apotekarsocieteten
Image
Image
Individualized Manufacturing and GMP - How Does It Work?
Emil Schwan, Pharmaceutical Inspector, Medical Products Agency, Uppsala
Image
Image
Precision Medicine in Immuno-Oncology
Sara Mangsbo, Associate Professor, Uppsala University & Chief Development Officer, Ultimovacs
Image
Image
A Flexible, Connected Approach to Individual Dosage Management
Martin Olovsson, CEO, OnDosis, Gothenburg
Image
Image
Panel Debate: Opportunities and Challenges for Precise Drug Substances & Drug Products
Emil Schwan, Pharmaceutical Inspector, Medical Products Agency, Uppsala
Image
Image
Sara Mangsbo, Associate Professor, Uppsala University & Chief Development Officer, Ultimovacs
Image
Image
Martin Olovsson, CEO, OnDosis, Gothenburg
Image
Image
Per Wessman, Head of Formulation, RISE Research Institutes of Sweden
Image
Image
16:40
Reconvene in main conference room
16:45

The Copenhagen Hospital Biobank and The Danish Blood Donor Study – Two Large-Scale National Biobanks for Health Research

Prof Dr Henrik Ullum, Professor & Chief Physician, Copenhagen Hospital Biobank Unit, Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital
Image
Image
17:15
Integrating Digital Health and Precision Cancer Medicine
Prof Tomi Mäkelä, Director, Helsinki Institute of Life Science & Executive Officer, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki
Image
Image Image
17:45
Close of conference followed by Complimentary Networking Drinks Reception
DAY 2 - Wednesday November 4, 2020
#nordicpmf
08:30
Welcome Refreshments and Networking
09:00
Opening Remarks from the Chair
09:10
The Economics of Precision Medicine: Establishing Value and Proving the Financial Business Case for Precision Medicine
  • Exploring the perception of “value” and the key criteria on which investment and funding decisions are made:
    • to what extent can evidence-based testing and technologies facilitate these decisions?
  • Examining how the disease and drug classification and reimbursement system could be changed to enable a broader, biological approach: how does this differ across different European countries?
  • Developing effective reimbursement mechanisms to meet the requirements of the payer and “justify” precision medicine
  • Finding an effective balance between value economics and optimum patient care
Prof Bengt Jönsson, Professor Emeritus of Health Economics, Stockholm School of Economics (SSE)
Image
Image
09:40

Patient’s Perspective: Patients as a Driving-Force to Advance Precision Medicine

10:40
Morning Refreshments & Networking
11:10
The programme will now split into 2 tracks. Delegates are invited to choose the track they would like to attend.
TRACK ONE
Data - Leveraging the Power of “Big Data” to Realise its Full Potential for Delivering Precision Medicine
One of the key challenges for the advancement of precision medicine is transforming the huge amount of genetic data being generated into a tool to improve disease classification, “unlock” diagnoses and identify new treatment options. As well as the significant privacy and trust issues to be overcome, there are a number of technical obstacles. Health data is not easily accessible by researchers, patients and doctors when and how they need it in order to deliver better outcomes; instead it is “siloed”; held in divergent systems in numerous different formats in huge unmanageable quantities. This session will explore new ways of managing, integrating and analysing biological and healthcare information to maximise its potential value.
Chair: Dr Valtteri Wirta, Director, Clinical Genomics Facility, Science for Life Laboratory & Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
Image
Image
Track 1
Strategies for Enhancing the Quality of Data Available & Optimise Its Use
  • Examining the key issues currently affecting data availability, affordability and quality 
  • Assessing what needs to be done to monitor this and ensure data gathered is as usable as possible:
    • benchmarking
    • harmonisation
    • standardisation
  • Identifying which technologies can facilitate the flow of health data
Dr Sharmini Alagaratnam, Principal Researcher, Precision Medicine Research Programme, DNV GL
Image
Image
11:30
Track 1
Unlocking the True Potential of Multi-Omics Data Through Integrated Bio-Informatics
  • Identifying the key challenges in multi-omics data utilisation and possible solutions
  • Assembling the right “toolbox” for optimum data integration and analysis:
    • developing robust and transparent bioinformatic pipelines to provide timely and useful clinical information 
    • using new data analysis tools to gain better insights from the information available 
    • techniques for reporting the findings in a coherent and useful way  
  • Exploring new methods for integrating genetic data from different sources to find the meaningful overlap:
    • selecting the most relevant variables from different -omics datasets and samples
    • techniques for extracting common information from different datasets for the same patients and classifying patients
  • Successfully translating multi-omics data into clinically actionable biomarkers
   Dr Antonio Andreu, Scientific Director, EATRIS
Image
Image
11:50
Track 1
Effectively Integrating Patient-Generated & Lifestyle Data into the Healthcare System to Optimise Its Use
  • Exploring how the increasing volume of behavioural and lifestyle data can be integrated appropriately with clinical data:
    • how to utilise patient led self-care data in healthcare - Finnish example
Anniina Pylsy, Planning Specialist, Kanta Services, The Social Insurance Institution of Finland (Kela)
Image
Image
11:10
TRACK TWO
Advancing Precision Medicine Through Multi-Omics Strategies
Deriving molecular signatures from multi-omics data has the potential to more accurately define disease, improve patient stratification and predict likely drug or therapy response. There have been many advances in the use of multi-omics data, however some omics are more developed than others. This session will explore what is being achieved with different -omics and how ready they are for clinical use.
Chair: Dr Ujjwal Neogi, Associate Professor of Virology, Division of Clinical Microbiology & Group Leader, LabMed, Karolinska Institutet &  Adjunct Associate Professor, University of Missouri, Columbia, USA
Image
Image Image
Track 2
A Multi-Omics Diagnostic Approach in a Rare Inborn Error of Metabolism
    Prof Dr Rikke Olsen, Associate Professor, The Research Unit for Molecular Medicine (MMF), Department of Clinical Medicine (DCM), Aarhus University Hospital
Image
Image
11:25
Track 2
Implementing Pharmacogenomics into Clinical Practice
Prof Dr Matthias Schwab, Head of the Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tübingen
Image
Image
11:40
Track 2
Metabolomics: Metabolic Profiling as An Early Diagnosis Tool for Precision Medicine
Prof Dr Vidya Velagapudi, Associate Director, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg
Image
Image
11:55
Track 2
Using Proteomics & Integrated Proteogenomics to Better Understand Molecular Profiles and Improve Disease Detection, Diagnosis & Prevention
12:10
Panel Q & A Discussion
12:30
Networking Lunch
13:30
Welcome Back - The afternoon session will also continue in 2 tracks. Delegates are again invited to choose which of the tracks they would like to attend
TRACK THREE
Diagnostics & Biomarker Development
A recognised bottleneck in the advancement of precision medicine is the identification, development and validation of appropriate predictive biomarkers. These are a vital tool to provide the link between research, clinical trials and implementation. This session will look at the development of innovative biomarkers and their potential use in clinical practice, as well as emerging diagnostic techniques for better disease prediction and prognosis.
Track 3
Exploring the Effective Development and Integration of Digital Biomarkers
  • Exploring the latest innovations in mobile, smart, cloud and self-diagnostic technologies for obtaining patient data and insights for use as digital biomarkers
  • Identifying the challenges to be overcome in using digital biomarkers and possible solutions:
    • reliability of technology and results
    • standardisation of results from patient technology and in a clinical setting
    • data privacy issues
  • Successfully leveraging the information generated to track trends and patterns for individuals and populations:
    • examining what tools are needed to effectively integrate e-health technology into clinical practice
    • assessing the implications for healthcare systems of patient self-management technologies and increased patient empowerment
  • Demonstrating the use of health-tech and patient-driven technology as diagnostic tools in practice 
13:50
Track 3
Developing Innovative Biomarkers for a Personalized Medicine Approach in Patients with Cardiovascular Disease
Prof Dr Agneta Siegbahn, Senior Professor, Department of Medical Sciences, Uppsala University
Image
Image
14:10
Track 3
Early Signalling Responses to Chemotherapy to Predict Survival in Acute Myeloid Leukemia
Prof Dr Bjørn Tore Gjertsen, Center for Cancer Biomarkers CCBIO, Department of Clinical Science, Precision Oncology Research Group, University of Bergen & Department of Internal Medicine, Hematology Section, Haukeland University Hospital
Image
Image
13:30
TRACK FOUR
Moving Beyond Genomics – The Development of Functional or Systems Precision Medicine
Genomic profiling is driving the development of precision medicine, particularly with regards to oncology. However, a key challenge is being able to match effective drugs to genomic profiles, which are often complex and unique to each patient. Furthermore, even when it is possible to target certain genes, it is not always clear which one should be prioritised, or which drug would be most effective. This session will explore how the development and application of functional analysis could be used as a precision medicine tool alongside genomic-focused approaches to improve targeted drug development and accelerate clinical implementation.
Chair: Dr Sigrid Skånland, Lab Leader & Researcher, Institute for Cancer Research, Oslo University Hospital
Image
Image
Track 4
Examining how Functional Assays Can Be Used as Diagnostic Tools to Facilitate the Development of Predictive Biomarkers for Precision Medicine
  • Determining the costs and time-scales of using functional testing and analysis compared to genomic approaches
  • To what extent can in-vitro methods using patient-derived calls (PDCs) deliver an appropriate response? Do they effectively mirror the patient and likely tumour mutation?
  • Exploring recent advances in modelling organoids and their likely implementation into clinical practice
Prof Dr Krister Wennerberg, Professor, Biotech Research & Innovation Centre (BRIC), University of Copenhagen
Image
Image
13:55
Track 4
Integrating Multi-Omic and Functional Drug Testing for Precision Medicine to Advance Effective Drug Development & Re-Purposing
Dr Päivi Östling, Associate Professor & Co-Principal Investigator, Kallioniemi Research Group, SciLifeLab
Image
Image
14:10
Track 4
Recent Innovations in Functional Analysis & Diagnostics
14:15
Panel Q & A Discussion
14:45
Afternoon Refreshments & Networking
15:10
A Final Plenary Session will Conclude the Afternoon
Making It A Reality: Effectively Implementing Precision Medicine Into Clinical Practice
This final, but perhaps most important, session will bring together the R&D advances and different approaches being taken to develop precision medicine that have been discussed throughout the day and explore how they can best be translated into clinical practice. It will discuss the challenges currently hindering this implementation and explore where and how changes need to be made in order to create better flexibility, foster innovation, and deliver precision medicine in reality.
Data-Driven Molecular Precision Medicine
Professor Dr Olli-Pekka Kallioniemi, Professor of Molecular Precision Medicine, Karolinska Institutet & Director, Science for Life Laboratory
Image
Image Image
15:25
Precision Medicine: Getting to the Heart of the Matter
This final, but perhaps most important, session will bring together the R&D advances and different approaches being taken to develop precision medicine that have been discussed throughout the day and explore how they can best be translated into clinical practice. It will discuss the challenges currently hindering this implementation and explore where and how changes need to be made in order to create better flexibility, foster innovation, and deliver precision medicine in reality.
Dr David O. Arnar, Chief of Cardiology, Landspitali - The National University Hospital, Iceland
Image
Image
15:40
Examining How Healthcare Systems Need to Adapt in Order to Truly Deliver Precision Medicine
  • Assessing the infrastructure, data and technology changes required to current healthcare systems in order to deliver a precision medicine approach
  • Research / Clinic interaction: Exploring how to translate broad genomic and multi-omic profiling data into actionable insights that can be used in clinics
  • Discovering innovative ways of reorganising healthcare systems with limited resources
  • Assessing the effectiveness of clinical trials and how they can facilitate precision medicine in practice
Dr Maj-Britt Juhl Poulsen, Team Leader & Executive Advisor, Danish Regions
Image
Image
15:55
Developing and Implementing Precision Medicine & Digital Health Communication & Training Programmes for Healthcare Professionals (HCPs)
  • Assessing how the role of HCPs will change in future and how they will need to adapt to deliver  healthcare, including digital health and precision medicine 
  • Effectively managing increasing patient empowerment
  • Communicating and convincing HCPs of the validity and potential of new personalised treatments and therapies
  • Training HCPs to analyse and effectively use the data available to them
16:10
Panel Q & A Discussion
16:40
Closing Remarks from the Chair and Close of Conference
With Special Thanks to Our Sponsors, Exhibitors and Partners
#nordicpmf
© Precision Medicine Forum